Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Expecting 10 Biosimilar Applications Submitted By End Of FY 2015

Executive Summary

The agency says it expects to receive three biosimilar marketing applications in fiscal year 2014 and another seven in FY 2015, as well as much more in program revenue.

Advertisement

Related Content

Apotex Biosimilar Goes To FDA, But May Enter Crowded Market
Celltrion’s Remicade Biosimilar Takes U.S. Regulatory Shortcuts
Biosimilars: Does Low BsUFA Fee Revenue Suggest Sponsor Interest Has Stalled?
How To Get A Meeting With FDA: Guidance Describes Formal Meetings For Biosimilars
Biosimilars Program Will Be “Under-Resourced” In Early Years As Industry Grows
FDA Sets Biosimilar Application Fees, But Is Silent On Volume Projections

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS056298

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel